LAVAL, QUEBEC--(Marketwire - March 05, 2008) - Warnex Inc. (TSX: WNX) today announced that its Medical Laboratories division has launched a new screening service for prostate cancer, the PCA3 assay. The Warnex PCA3 screening service for prostate cancer uses advanced PCR technology to detect mRNA from the prostate cancer gene 3 (PCA3). Warnex is the first laboratory to offer this service in Canada.
